0.73+0.00+0.14%
12:50:59 PM EDT 6/17/2024BTT
Plus500. 81% of retail CFD accounts lose money
| News | Analyst Data | Analyst Opinions | Insider Activity | Dividend Calendar |
New: Online Broker Comparison!Learn more about the best online brokers in our new comparison! Find out more!
On Friday 06/14/2024 the closing price of the Equillium Inc Registered Shs share was $0.73 on BTT.Compared to the opening price on Friday 06/14/2024 on BTT of $0.72, this is a gain of 1.38%.Equillium Inc Registered Shs's market capitalization is $25.10 M by 35.25 M shares outstanding.
Equillium Stock Snapshot
0.71
Bid
200.00
Bid Size
0.73
Ask
200.00
Ask Size
6/17/2024
Date
12:50 PM
Time
0.00
Volume
0.73
Prev. Close
0.00
Open
25.16 M
Market Cap in USD
35.25 M
Number of Shares
0.47
52 Week Low
3.20
52 Week High
0.73
0.00
Dividend in USD
0.00
Dividend Yield
54.04
Free Float in %
-0.38
EPS in USD
0.64
Book Value per Share in USD
-0.63
Cash Flow per Share in USD
Equillium NewsMore News
Seeking Alpha
Equillium to join Russell Microcap Index
TipRanks
Analysts Conflicted on These Healthcare Names: Equillium (EQ), Lexeo Therapeutics, Inc. (LXEO) and Teladoc (TDOC)
TipRanks
Buy Rating Affirmed: Equillium’s EQ101 Shows Promising Results in Phase 2 Alopecia Areata Study
TipRanks
Buy Rating Affirmed for Equillium on Milestones and Financial Prospects
Historical Prices for Equillium
| Date | Open | Close | Daily High | Daily Low |
|---|
Price change over selected period:0%0
Equillium Analyst Data
Total Analysts: 13
Buy Ratings: 13 Neutral Ratings: 0 Sell Ratings: 0
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price *Price Target
Lowest: 2.80 Median: 6.83 Highest: 20.00
*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.
Equillium Analyst Opinions
- All
- Buy
- Hold
- Sell
| Date | Analyst | Rating | Price | |||
|---|---|---|---|---|---|---|
| 06/05/24 | H.C. Wainwright & Co. | Maintained Buy | $5 | gut | ||
| 05/17/24 | H.C. Wainwright & Co. | Maintained Buy | $5 | gut | ||
| 04/02/24 | H.C. Wainwright & Co. | Maintained Buy | $5 | gut | ||
| 12/26/23 | H.C. Wainwright & Co. | Maintained Buy | $4 | gut | ||
| 11/13/23 | H.C. Wainwright & Co. | Maintained Buy | $4.5 | gut | ||
| 08/14/23 | Cantor Fitzgerald | Maintained Buy | $2.79999995231628 | gut | ||
| 08/14/23 | H.C. Wainwright & Co. | Maintained Buy | $5.5 | gut | ||
| 05/15/23 | H.C. Wainwright & Co. | Maintained Buy | $5.5 | gut | ||
| 05/01/23 | H.C. Wainwright & Co. | Maintained Buy | $5.5 | gut | ||
| 03/24/23 | Stifel, Nicolaus & Co., Inc. | Maintained Buy | $7 | gut | ||
| 02/08/23 | SVB Leerink | Maintained Buy | $7 | gut | ||
| 09/27/22 | H.C. Wainwright & Co. | Maintained Buy | $20 | gut | ||
| 09/08/22 | SVB Leerink | Maintained Buy | $12 | gut |
Equillium Estimates* in USD
| 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|
| Revenue | 42 | 26 | 31 | - | 87 |
| Dividend | - | - | - | - | - |
| Dividend Yield (in %) | - | - | - | - | - |
| EPS | -0.10 | -0.50 | -0.80 | -1.46 | -0.82 |
| P/E Ratio | -7.13 | -1.42 | -0.89 | -0.49 | -0.87 |
| EBIT | -4 | -21 | -47 | -97 | -55 |
| EBITDA | - | - | - | - | - |
| Net Profit | -3 | -19 | -41 | -87 | -49 |
| Net Profit Adjusted | -7 | 12 | - | - | - |
| Pre-Tax Profit | -3 | -19 | -41 | -87 | -49 |
| Net Profit (Adjusted) | - | - | - | - | - |
| EPS (Non-GAAP) ex. SOE | -0.32 | -0.67 | - | - | - |
| EPS (GAAP) | -0.32 | -0.40 | 0.09 | - | - |
| Gross Income | 38 | 52 | 31 | - | 80 |
| Cash Flow from Investing | -3 | 0 | -2 | - | - |
| Cash Flow from Operations | -25 | -26 | 13 | - | - |
| Cash Flow from Financing | 43 | 225 | - | - | - |
| Cash Flow per Share | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - |
| Free Cash Flow per Share | - | - | - | - | - |
| Book Value per Share | - | - | - | - | - |
| Net Debt | -97 | -152 | -248 | -142 | -68 |
| Research & Development Exp. | 32 | 32 | 56 | 57 | 59 |
| Capital Expenditure | 0 | 0 | 2 | - | - |
| Selling, General & Admin. Exp. | 13 | 14 | 23 | 39 | 75 |
| Shareholder’s Equity | 10 | 98 | 113 | - | - |
| Total Assets | 22 | 114 | 130 | - | - |
| Previous Quarter ending 03/31/24 | Current Quarter ending 06/30/24 | Next Quarter ending 09/30/24 | Current Year ending 12/31/24 | Next Year ending 12/31/25 | |
|---|---|---|---|---|---|
| Earnings Estimates | |||||
| No. of Analysts | 4 | 4 | 4 | 4 | 4 |
| Average Estimate | -0.148 USD | -0.150 USD | 0.405 USD | -0.100 USD | -0.503 USD |
| Year Ago | -0.110 USD | -0.100 USD | -0.110 USD | -0.380 USD | -0.100 USD |
| Publish Date | 5/9/2024 | 8/12/2024 | 11/12/2024 | - | - |
| Revenue Estimates | |||||
| No. of Analysts | 4 | 4 | 4 | 4 | 4 |
| Average Estimate | 7 USD | 6 USD | 25 USD | 42 USD | 26 USD |
| Year Ago | 9 USD | 9 USD | 9 USD | 36 USD | 42 USD |
| Publish Date | 5/9/2024 | 8/12/2024 | 11/12/2024 | - | - |
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet
Income Statements in Mio. USD
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Sales | 36.08 | 15.76 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change of sales in % | 128.97 | - | - | - | - | - | - |
| Gross profit on sales | 35.96 | 15.64 | -0.07 | -0.05 | -0.02 | -0.01 | 0.00 |
| Gross profit on sales change in % | 129.90 | - | -60.00 | -95.65 | -276.93 | -4,901.64 | - |
| Operating income | -14.52 | -39.03 | -37.79 | -29.55 | -26.73 | -8.62 | -1.71 |
| Operating income change in % | 62.79 | -3.28 | -27.88 | -10.55 | -210.22 | -403.23 | - |
| Income before tax | -12.76 | -62.43 | -39.05 | -29.81 | -25.60 | -13.25 | -2.26 |
| Income before tax change in % | 79.57 | -59.86 | -30.99 | -16.46 | -93.20 | -485.82 | - |
| Income after tax | -13.34 | -62.43 | -39.05 | -29.81 | -25.60 | -13.25 | -2.26 |
| Income after tax change in % | 78.64 | -59.86 | -30.99 | -16.46 | -93.20 | -485.82 | - |
Balance Sheet in Mio. USD
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Total liabilities | 27.96 | 46.48 | 18.90 | 15.57 | 13.69 | 2.23 | 9.40 |
| Long-term liabilities per share | 0.01 | 0.42 | 0.34 | 0.34 | 0.56 | 0.01 | 0.51 |
| Equity | 22.57 | 31.94 | 66.51 | 69.85 | 41.85 | 64.94 | -2.25 |
| Equity change in % | -29.33 | -51.97 | -4.79 | 66.92 | -35.55 | - | - |
| Balance sheet total | 50.53 | 78.42 | 85.41 | 85.43 | 55.54 | 67.16 | 7.15 |
| Balance sheet total change in % | -35.57 | -8.18 | -0.03 | 53.82 | -17.31 | 839.15 | - |
Key Data in USD
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Sales per share | 1.04 | 0.47 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| P/E ratio (year end quote, basic EPS) | - | - | - | - | - | - | - |
| P/E ratio (ear end quote, diluted EPS) | - | - | - | - | - | - | - |
| P/E ratio (year end quote) | - | - | - | - | - | - | - |
| Dividend yield in % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Equity ratio in % | 44.67 | 40.73 | 77.87 | 81.77 | 75.35 | 96.68 | -31.49 |
| Debt ratio in % | 55.33 | 59.27 | 22.13 | 18.23 | 24.65 | 3.32 | 131.49 |
Equillium Insider Activity
| Name | Date | shares traded | shares held | Price | type (sell/buy) | option |
|---|---|---|---|---|---|---|
| Rothman Joel | 12/07/2023 | 8,804.00 | 58,150.00 | 0.58 | Buy | No |
| Keyes Jason A | 12/07/2023 | 8,805.00 | 58,913.00 | 0.58 | Buy | No |
| Zedelmayer Christine | 12/07/2023 | 8,804.00 | 135,246.00 | 0.58 | Buy | No |
| Rothman Joel | 06/08/2023 | 15,000.00 | 49,346.00 | 0.56 | Buy | No |
| Keyes Jason A | 06/08/2023 | 15,000.00 | 50,108.00 | 0.56 | Buy | No |
| Zedelmayer Christine | 06/08/2023 | 15,000.00 | 126,442.00 | 0.56 | Buy | No |
| Rothman Joel | 12/08/2022 | 3,821.00 | 34,346.00 | 1.19 | Buy | No |
| Keyes Jason A | 12/08/2022 | 4,444.00 | 35,108.00 | 1.19 | Buy | No |
| Keyes Jason A | 08/28/2022 | 7,000.00 | 77,720.00 | 2.83 | Sell | No |
| Rothman Joel | 06/09/2022 | 6,244.00 | 30,525.00 | 1.85 | Buy | No |
| Zedelmayer Christine | 06/09/2022 | 9,033.00 | 111,442.00 | 1.85 | Buy | No |
| Keyes Jason A | 06/05/2022 | 5,000.00 | 84,720.00 | 2.52 | Sell | No |
| Keyes Jason A | 04/03/2022 | 8,000.00 | 89,720.00 | 3.18 | Sell | No |
| Keyes Jason A | 12/09/2021 | 5,585.00 | 23,296.00 | 2.35 | Buy | No |
| Rothman Joel | 12/09/2021 | 1,290.00 | 24,281.00 | 2.35 | Buy | No |
| Keyes Jason A | 11/30/2021 | 5,000.00 | 97,720.00 | 5.08 | Sell | No |
| Zedelmayer Christine | 11/15/2021 | 4,084.00 | 94,759.00 | 5.49 | Sell | No |
| Zedelmayer Christine | 11/15/2021 | 7,350.00 | 102,409.00 | 5.49 | Sell | No |
| Zedelmayer Christine | 11/15/2021 | 15,000.00 | 109,759.00 | 2.45 | Buy | No |
| Zedelmayer Christine | 11/15/2021 | 8,334.00 | 98,843.00 | 2.45 | Buy | No |
| Connelly Stephen | 10/05/2021 | 2,467.00 | 993,000.00 | 7.01 | Sell | No |
| Connelly Stephen | 10/05/2021 | 5,625.00 | 993,000.00 | 7.01 | Sell | No |
| Connelly Stephen | 10/05/2021 | 2,467.00 | 995,467.00 | 2.80 | Buy | No |
| Connelly Stephen | 10/05/2021 | 5,625.00 | 998,625.00 | 4.75 | Buy | No |
| Keyes Jason A | 09/26/2021 | 8,000.00 | 102,720.00 | 6.74 | Sell | No |
Equillium Dividend Calendar
| Date | Name | Dividend | *yield | Currency |
|---|---|---|---|---|
| 2023 | Equillium Inc Registered Shs | 0.00 | 0.00 | USD |
| 2022 | Equillium Inc Registered Shs | 0.00 | 0.00 | USD |
| 2021 | Equillium Inc Registered Shs | 0.00 | 0.00 | USD |
| 2020 | Equillium Inc Registered Shs | 0.00 | 0.00 | USD |
| 2019 | Equillium Inc Registered Shs | 0.00 | 0.00 | USD |
| 2018 | Equillium Inc Registered Shs | 0.00 | 0.00 | USD |
| 2017 | Equillium Inc Registered Shs | - | - | USD |
*Yield of the Respective Date
Equillium Inc Registered Shs Calendar
| Event | Estimate | Info | Date |
|---|---|---|---|
| Earnings Report | -0.150 USD | Q2 2024 Earnings Release | 08/12/2024 |
| Earnings Report | 0.405 USD | Q3 2024 Earnings Release | 11/12/2024 |
| Earnings Report | - | Q4 2024 Earnings Release | 03/26/2025 |
| Earnings Report | - | Q1 2025 Earnings Release | 05/08/2025 |
Equillium Inc Registered Shs Past Events
| Event | Actual EPS | Info | Date |
|---|---|---|---|
| Annual General Meeting | - | Annual General Meeting | 05/22/2024 |
| Earnings Report | -0.080 USD | Q1 2024 Earnings Release | 05/09/2024 |
| Earnings Report | -0.070 USD | Q4 2023 Earnings Release | 03/25/2024 |
Equillium Profile
Equillium, Inc. engages in the development of products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. Its product pipeline includes EQ001, which is a monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. The company was founded by Daniel Mark Bradbury, Bruce D. Steel, and Stephen Connelly in March, 2017 and is headquartered in La Jolla, CA.
Equillium Shareholder
| Owner | in % |
|---|---|
| Freefloat | 54.04 |
| Decheng Capital Management Iii Cayman LLC | 12.61 |
| Decheng Capital LLC | 12.61 |
| Decheng Capital LLC | 12.61 |
| Daniel Mark Bradbury | 10.53 |
| Bruce D. Steel, CFA, MBA | 10.53 |
| Biocon Ltd. | 6.57 |
| Takeda Pharmaceutical Co., Ltd. | 5.23 |
| Victory RS Small Cap Growth Fund | 4.31 |
| Victory Capital Management, Inc. (Investment Management) | 3.84 |
| Stephen Connelly, PhD, MBA | 2.82 |
| Victory Science & Technology Fund | 2.81 |
| Franklin Advisers, Inc. | 2.54 |
| Vanguard Group, Inc. (Subfiler) | 2.37 |
| Samsara Biocapital LLC | 1.75 |
Shareholder percentage totals can add to more than 100% because some holders are included in the free float.
